

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 65092

Title: Real World Evidence on First and Second Line Palliative Chemotherapy in Advanced Pancreatic Cancer

Reviewer's code: 03727100

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Assistant Professor, Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: Sweden

Manuscript submission date: 2021-02-28

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-03-09 12:09

Reviewer performed review: 2021-03-15 12:31

Review time: 6 Days

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Thank you for giving me a chance to review the manuscript that described the detail of chemotherapy in advanced pancreatic cancer. This is a good review manuscript, however, I have some queries. 1. What is the full spell of FFX (Page 3, line 3)? 2. Please add the citation of MPACT trial (Page 5, line 20)? 3. Why didn't authors add a report (citation number 20) in Table 1? 4. Would you please teach me the reasons of a sentence "only 20% of the real-world PDAC population would be eligible for treatment" (Page 6, line 22)? 5. A Swedish study was not involved Table 3 (Page 8, line 3-7)? 6. What is the full spell of OS2 (Page 9, line 23)? 7. Would you please add the explanations of abbreviations (mOS, mPFS, GnP, FFX, p, L, etc...) in all tables? 8. Can authors add information about the number of locally advanced or metastatic pancreatic cancer patients in tables? 9. In table 1, albumin < 37, age < 65 are the conditions of worse survival. Would you please add the description in table 1? 10. Would you please add the citation numbers in all tables? 11. In table 4, the 2L regimen of a report written by Nguyen 2017 was GnP (n = 30), Gem (n = 8), BSC (n = 22)? 12. In a report written by Matsumoto et al 2020 (Table 5), the mOS of FFX was 6.9 months. On the other hand, the mOS of modified FFX was 12.8 months. Was there a significant difference between the mOS of FFX and the mOS of modified FFX? 13. In table 5, "1L rwegimen" was wrong. 14. Can you add the description about adverse events in all tables? If you can't do it, you can't help it.